,Name,VH,VL,Light chain class,Type,Original mAb Isotype or Format,Clinical Status,HEK Titer (mg/L),Fab Tm by DSF (°C),SGAC-SINS AS100 ((NH4)2SO4 mM),HIC Retention Time (Min)a,SMAC Retention Time (Min)a,Slope for Accelerated Stability,Poly-Specificity Reagent (PSR) SMP Score (0-1),Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) ∆λmax (nm) Average,CIC Retention Time (Min),CSI-BLI Delta Response (nm),ELISA,BVP ELISA
0,abituzumab,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,kappa,ZU,IgG2,Phase 2,89.5554580290071,75.5,900.0,9.227,8.725,0.05563,0.16666613356377663,1.4588608195349846,8.620999999999997,0.0,1.1373747390491518,2.7207986688851915
1,abrilumab,QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,kappa,HU,IgG2,Phase 2,100.223196340551,71.0,900.0,9.413,8.699,0.02829,0.0,-0.9285255875093593,8.383999999999999,-0.02,1.124623995718366,1.8183028286189689
2,adalimumab,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,kappa,HU,IgG1,Approved,134.928638213675,71.0,900.0,8.816,8.672,0.05069,0.0,1.062328361664409,8.865000000000002,-0.01,1.0755145072525718,1.4881863560732114
3,alemtuzumab,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,kappa,ZU,IgG1,Approved,144.653542801851,74.5,1000.0,8.769,8.672,0.06431,0.0,-0.7891989854609082,8.513999999999998,-0.02,1.1614913553524202,1.4642262895174707
4,alirocumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,kappa,HU,IgG1,Approved,69.2323451150256,71.5,900.0,9.036,8.681,0.0292,0.0,1.2305105389538458,8.757,-0.01,1.1962236913634507,2.179700499168053
5,anifrolumab,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,kappa,HU,IgG1,Phase 3,82.046820982102,62.5,700.0,8.799,8.629,0.0708,0.0,-0.5613971335854627,8.488999999999999,-0.02,1.157449676152755,1.6232945091514144
6,atezolizumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,kappa,ZU,IgG1-no-glyco,Approved,164.085804300914,73.5,300.0,13.353,19.283,0.0556,0.06581238416122195,14.97112171419135,10.759999999999996,0.06,1.2947458411000836,6.1973782771535575
7,bapineuzumab,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,151.091649573153,73.0,1000.0,8.855,8.655,0.07017,0.0,-0.7342555803773684,8.619,0.06,1.2089498235875755,3.548752079866889
8,basiliximab,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,kappa,XI,IgG1,Approved,107.461587632875,60.5,0.0,9.578,8.576,0.0476,0.39716368784365835,28.757059110614296,9.448999999999996,0.0,1.2013275867288382,2.1385767790262173
9,bavituximab,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,kappa,XI,IgG1,Phase 3,45.11027388324556,59.5,0.0,11.499,12.689,0.0404,0.5570368731420577,29.851202382637435,11.394999999999996,-0.01,1.3154556972115918,1.6928838951310858
10,belimumab,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,lambda,HU,IgG1,Approved,10.4727274459097,60.0,800.0,10.461,9.267,0.1304,0.0,0.7712519507842107,8.588,-0.03,3.6095347235354525,12.228951747088184
11,benralizumab,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,146.7126837302625,76.0,800.0,9.467,9.09,0.0243,0.3537118134191836,5.977932685387823,9.628,-0.01,1.2312629702928908,1.4247191011235956
12,bevacizumab,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,kappa,ZU,IgG1,Approved,49.9785778269993,63.5,700.0,11.772,11.07,0.2198,0.0,0.790219867914591,9.822,-0.02,1.2859140710563495,2.7846921797004995
13,bimagrumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,lambda,HU,IgG1,Phase 3,150.238850504352,72.0,0.0,10.125,8.829,0.09126,0.6965555618675863,29.64509490013043,12.328000000000001,0.1,1.5486084368278836,5.327787021630615
14,blosozumab,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,kappa,ZU,IgG4-CPPC,Phase 2,120.00975163796,70.5,600.0,9.241,8.626,0.1252,0.2082434217055435,11.472475883134644,8.866000000000001,0.46,13.177765048787677,12.84792013311148
15,bococizumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,kappa,ZU,IgG2,Phase 3,95.7869214399117,67.0,0.0,10.179,9.108,0.067,0.7601842867698116,29.64509490013043,10.595,0.5,13.49645762735782,18.87720465890183
16,brentuximab,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,kappa,XI,IgG1-ADC,Approved,268.061982174822,72.0,800.0,10.535,8.683,-0.003086,0.2474876787715646,-0.5424265510343164,8.550999999999997,-0.03,4.211600067891459,2.2429284525790347
17,briakinumab,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,lambda,HU,IgG1,Phase 3,121.99223381709,71.5,0.0,9.359,8.737,0.1054,0.5560592534086306,29.64509490013043,10.394,0.02,4.829995936621175,10.217637271214642
18,brodalumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,kappa,HU,IgG2,Phase 3,150.86258566485,74.5,900.0,9.079,8.743,0.01717,0.2654903000693104,11.207608587538333,8.971000000000002,-0.01,1.4751250398765592,2.9257903494176376
19,canakinumab,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,kappa,HU,IgG1,Approved,45.7249289561313,72.0,800.0,9.321,8.727,0.03791,0.0,0.6699380678068486,8.635,0.0,1.1954184187031964,2.545757071547422
20,carlumab,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,kappa,HU,IgG1,Phase 2,243.323478252909,69.5,700.0,11.167,9.31,0.07491,0.21158230649501245,-0.4380321771813363,8.62,-0.02,2.7610833976722176,8.879201331114809
21,certolizumab,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,kappa,ZU,FabPEG,Approved,186.709368605726,81.5,500.0,11.478,10.815,0.04289,0.0,0.16309536708509598,9.313999999999998,-0.01,1.1438183996579112,1.647920133111481
22,cetuximab,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,kappa,XI,IgG1,Approved,109.160445482209,68.5,400.0,10.11,8.91,0.05474,0.0,1.2999612612528957,8.906,-0.04,1.0932803630555306,1.0855241264559068
23,cixutumumab,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,lambda,HU,IgG1,Phase 2,154.259630219969,73.5,0.0,11.76,10.723,0.1617,0.6570238935398882,29.64509490013043,9.664,0.38,3.7663443197715445,11.90415973377704
24,clazakizumab,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,kappa,ZU,IgG1,Phase 2,113.477346572884,69.5,800.0,9.568,8.871,0.05306,0.0,0.9300457109314907,8.729000000000001,-0.03,1.2815538046885984,4.1151414309484196
25,codrituzumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,kappa,ZU,IgG1,Phase 2,66.347407560354,73.0,1000.0,8.836,8.592,0.255,0.14798660301481634,-0.28571893838238765,8.453999999999999,-0.01,9.418865043753986,14.874542429284528
26,crenezumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,kappa,ZU,IgG4-CPPC,Phase 3,149.265976775631,72.0,700.0,10.031,8.703,0.04786,0.10493606776312797,6.37079988498525,8.899,0.0,1.1333962139863132,2.7806988352745425
27,dacetuzumab,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,128.4522155567586,68.0,1000.0,8.466,8.614,0.0033,0.0,-0.01467616676150868,8.466999999999999,-0.04,1.0793259925499534,1.3352059925093631
28,daclizumab,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,kappa,ZU,IgG1,Approved,245.10792344452,74.0,900.0,9.286,8.751,0.02794,0.0,-0.11058643018373004,8.476,-0.02,1.1803655455457376,1.4143094841930115
29,dalotuzumab,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,82.4173401920308,77.0,800.0,9.891,8.704,0.1466,0.39964812495337587,13.680590019875657,9.118,0.14,2.8986549663190946,8.253577371048253
30,daratumumab,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,kappa,HU,IgG1,Approved,233.33429841855,71.0,800.0,9.514,8.926,0.06363,0.0,1.80923047610872,8.854999999999999,0.0,1.2135841080988004,3.151414309484193
31,denosumab,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,kappa,HU,IgG2,Approved,134.16784639303,69.5,1000.0,8.501,8.603,0.01043,0.0,5.90792488228362,8.811,0.11,5.917965726038389,17.74975041597338
32,dinutuximab,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,kappa,XI,IgG1,Approved,76.4288197947546,69.0,800.0,9.833,8.963,0.0098,0.3027408437092615,3.635205695940343,9.405,-0.02,1.0308868202823889,1.691760299625468
33,drozitumab,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,lambda,HU,IgG1,Phase 2,22.0688960178219,63.0,0.0,9.29,8.716,0.02829,0.0,29.64509490013043,8.789999999999997,0.04,1.096796901037131,1.4795341098169716
34,duligotuzumab,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,192.582804385907,67.5,0.0,10.206,8.938,0.05514,0.3344399631930372,29.64509490013043,9.53,0.6,8.539747695728627,9.630615640599002
35,dupilumab,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,kappa,HU,IgG4-CPPC,Phase 3,163.549147322201,76.5,700.0,10.159,9.009,0.02874,0.14687611364834163,10.804212296248883,9.751999999999997,-0.01,8.694358141880139,19.270549084858573
36,eculizumab,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,kappa,ZU,IgG24,Approved,226.468531780092,66.0,700.0,10.41,9.277,0.008,0.0,0.043333,8.498999999999999,-0.04,0.9594280678530325,2.99550561797752
37,efalizumab,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,kappa,ZU,IgG1,Approved,166.9923436829148,72.5,900.0,8.668,8.641,0.0,0.0,0.681275549075847,8.541999999999998,-0.02,0.9829102702195125,1.238202247191011
38,eldelumab,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,kappa,HU,IgG1,Phase 2,89.2530533728545,59.5,500.0,12.422,25.0,0.0998,0.0,1.2125200258514,10.155999999999997,-0.02,1.1090934181246197,1.7470881863560732
39,elotuzumab,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,kappa,ZU,IgG1,Approved,213.190600445939,83.5,700.0,10.314,9.288,0.0,0.0,-0.22446891023006735,8.469,-0.03,0.9780417679849919,1.2647940074906368
40,emibetuzumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,kappa,ZU,IgG4-CPPC,Phase 2,98.7489181018493,71.5,0.0,9.638,8.684,0.04114,0.6431427690118359,29.64509490013043,9.528,0.06,3.3000830869543307,8.32945091514143
41,enokizumab,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,kappa,ZU,IgG1,Phase 2,239.819012639097,68.0,600.0,12.934,10.881,0.08966,0.1258283523473987,1.5335529590210266,9.028,-0.02,1.1734171887827547,3.2392678868552416
42,epratuzumab,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,kappa,ZU,IgG1,Phase 3,78.2305721688696,65.0,900.0,9.189,8.629,0.02629,0.13091472438610505,3.0141872185730136,8.688999999999998,-0.01,1.4745521259964696,2.3427620632279536
43,etrolizumab,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,173.842456075648,76.0,900.0,9.322,8.77,0.2009,0.4203780747334936,2.01764560912522,8.767999999999999,-0.03,2.18207134775561,4.228951747088186
44,evolocumab,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,lambda,HU,IgG2,Approved,260.677127753984,65.0,700.0,10.355,9.13,0.0298,0.20433296002462253,2.236430607880717,9.254,-0.01,1.7544526538610825,1.7544093178036606
45,farletuzumab,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,220.817623863655,75.5,800.0,9.491,9.065,0.006029,0.0,-0.5019252748286357,8.687,-0.01,1.073797051762033,1.3217970049916803
46,fasinumab,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,kappa,HU,IgG4-CPPC,Phase 3,110.37448729273,71.0,900.0,10.026,8.715,0.06657,0.0,-0.6719270715475414,8.358999999999996,-0.02,1.1568614093693428,2.5271214642262896
47,fezakinumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,lambda,HU,IgG1,Phase 2,141.45349362403,69.0,600.0,11.798,13.709,0.06932,0.26471190300265457,2.5018396062184003,11.259999999999996,-0.0158,1.145612600241716,2.146422628951747
48,ficlatuzumab,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,kappa,ZU,IgG1,Phase 2,249.025765193707,75.0,900.0,9.421,8.882,0.04614,0.0,-0.8937858080471764,8.488000000000001,-0.02,1.1338843592183554,1.2332778702163063
49,figitumumab,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,kappa,HU,IgG2,Phase 3,119.916767611708,66.5,0.0,10.745,9.86,0.06446,0.37895750408777384,29.64509490013043,10.533,0.02,2.893762036891925,5.650582362728786
50,fletikumab,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,HU,IgG4-CPPC,Phase 2,220.376225219369,71.5,700.0,11.038,9.143,0.01897,0.0,-0.12545780929341765,8.473999999999998,-0.02,1.024451224557659,1.4083194675540764
51,foralumab,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,kappa,HU,IgG1,Phase 2,174.435087528376,66.0,0.0,9.842,8.574,0.03766,0.37171538406104226,28.085284038746863,9.324,0.0,4.767633761341637,4.711480865224626
52,fresolimumab,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,kappa,HU,IgG4,Phase 2,166.036557375438,74.0,700.0,10.875,9.145,0.05526,0.0,-0.5150833213308835,8.466,-0.02,1.3001810808363088,3.5128119800332778
53,fulranumab,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,HU,IgG2,Phase 3,142.018924215224,68.5,900.0,9.328,9.342,0.07229,0.18767856144527562,11.560721017420292,9.345999999999998,0.0,1.8493078235489149,6.9231281198003325
54,galiximab,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,lambda,XI,IgG1,Phase 2,174.116871715928,67.5,600.0,12.198,14.77,0.03135,0.0,1.0937136443025857,8.87,-0.02,1.213663041666796,3.810316139767055
55,ganitumab,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,kappa,HU,IgG1,Phase 3,229.439869516154,78.5,800.0,9.334,8.77,0.01174,0.5528448378515598,4.77483289417163,9.482000000000001,-0.01,1.29515577815994,4.907154742096505
56,gantenerumab,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,kappa,HU,IgG1,Phase 3,162.65901137397,77.5,1000.0,9.004,8.487,0.06671,0.5526000371608855,6.957989416174726,8.709000000000001,0.1,13.820190243915357,22.746089850249582
57,gemtuzumab,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,kappa,ZU,IgG4-ADC,Approved,171.299784622482,72.5,500.0,12.259,13.931,0.04534,0.0,1.0200510475198838,9.106,-0.01,1.080083574769414,1.6978369384359402
58,gevokizumab,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,kappa,ZU,IgG2,Phase 3,136.360640752103,71.5,1000.0,8.828,8.607,0.07129,0.0,-0.5147700660009676,8.578999999999999,-0.03,1.1800797913129024,1.9314475873544092
59,girentuximab,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,kappa,XI,IgG1,Phase 3,30.721829915697,63.0,1000.0,9.081,8.683,0.03154,0.0,-0.7518211058788499,8.524000000000001,-0.04,1.0901430323375536,1.393677204658902
60,glembatumumab,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,kappa,HU,IgG2,Phase 2,152.7123452567094,70.5,0.0,13.68,25.0,0.303,0.166106669274089,28.880634956572568,13.5,0.01,1.0632913221183808,2.215355805243446
61,golimumab,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,kappa,HU,IgG1,Approved,163.238323057107,70.0,0.0,11.359,12.747,0.06274,0.23400782072645826,22.965397316589065,11.23,-0.01,1.3092959757129294,2.712146422628952
62,guselkumab,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,lambda,HU,IgG1,Phase 3,167.340128579443,69.5,700.0,11.403,9.195,0.1931,0.46933863293249334,3.3671961867062934,10.109,0.02,1.541175938153107,5.867554076539101
63,ibalizumab,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,kappa,ZU,IgG4,Phase 3,133.2826330317606,72.0,800.0,10.237,9.771,0.0393,0.0,-0.33930425681300336,8.659999999999997,-0.03,0.9931422443300497,1.1262172284644194
64,imgatuzumab,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,kappa,ZU,IgG1,Phase 2,187.708496613097,71.5,800.0,10.09,8.898,0.06543,0.0,0.8938737657378684,8.994000000000002,-0.01,5.014940855575772,11.774376039933443
65,infliximab,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,kappa,XI,IgG1,Approved,6.58114599258111,64.5,0.0,10.36,8.888,0.1812,0.0,29.64509490013043,9.011,0.05,1.03683210868708,1.3717138103161397
66,inotuzumab,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,kappa,ZU,IgG4-ADC,Phase 3,169.767061734025,83.0,800.0,9.717,9.052,0.02517,0.2500082588538663,4.029670812855627,9.294999999999996,0.01,3.180204855314145,5.39567387687188
67,ipilimumab,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,kappa,HU,IgG1,Approved,169.561868339531,73.0,400.0,11.57,12.981,0.03963,0.22963113892764184,10.413098751574681,10.941000000000003,0.01,1.0524254712559482,1.691846921797005
68,ixekizumab,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,kappa,ZU,IgG4-CPPC,Approved,97.2774327422424,83.0,500.0,10.936,9.082,0.1614,0.8098172517111,19.952342859717298,9.635999999999997,0.11,8.797459757651835,10.398668885191348
69,lampalizumab,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,kappa,ZU,Fab,Phase 3,187.075401757929,67.0,800.0,9.25,8.765,0.08749,0.0,0.49417672258675766,8.455,-0.03,1.108847668199257,1.340432612312812
70,lebrikizumab,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,kappa,ZU,IgG4-CPPC,Phase 3,61.607125235924,66.0,500.0,12.381,15.71,0.0047,0.0,0.25532621011882334,9.070999999999996,-0.04,0.962254096761123,1.4561797752808987
71,lenzilumab,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,kappa,HU,IgG1,Phase 2,184.74275801653,74.0,0.0,8.722,8.605,0.03277,0.6551284845893702,29.64509490013043,10.121999999999998,0.02,14.459031329082327,19.604658901830284
72,lintuzumab,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,229.970847955366,75.5,700.0,10.874,9.428,0.048,0.0,0.8859881084878957,8.933000000000002,-0.02,1.045706347729163,1.254575707154742
73,lirilumab,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,kappa,HU,IgG4-CPPC,Phase 2,270.480296548054,70.0,300.0,25.0,25.0,0.00174,0.18291384199503324,20.998948134543898,10.562,0.04,1.2695558152902904,3.5494176372712145
74,lumiliximab,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,kappa,XI,IgG1,Phase 2,86.2730393740933,64.5,800.0,9.545,8.782,0.06686,0.1448969343845078,1.4435487891722294,8.815,-0.02,1.1379105646124137,2.2183028286189685
75,matuzumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,224.328820629927,72.0,900.0,9.84,8.834,0.0164,0.0,-0.9272078922528316,8.635,-0.03,1.0598553668783508,1.0276206322795345
76,mavrilimumab,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,lambda,HU,IgG4,Phase 2,150.548852590834,68.5,700.0,10.296,8.671,0.04903,0.0,-0.7787536595715207,8.496,-0.01,1.2130818227431415,2.161730449251248
77,mepolizumab,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,kappa,ZU,IgG1AA-mut,Approved,221.475176577629,78.5,900.0,9.238,8.816,0.04451,0.0,-0.9566370687348313,8.408,-0.04,1.131191260106393,1.0515806988352745
78,mogamulizumab,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,kappa,ZU,IgG1-glyco,Approved,89.7679294665026,68.5,800.0,9.641,8.82,0.03631,0.0,-0.5117615211688626,8.630999999999998,-0.02,1.1182820677553225,2.1657237936772047
79,motavizumab,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,kappa,ZU,IgG1,Phase 3,133.551594970658,86.0,800.0,9.689,8.82,0.04454,0.0,2.5227630302447666,8.660000000000002,-0.01,1.22954028386928,5.3603993344425955
80,muromonab,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIK,kappa,XIa,IgG2a,Approved,113.522880356409,74.5,1000.0,8.899,8.578,0.03829,0.17589163469089858,2.311512650397803,9.047999999999996,0.01,1.408897007528137,3.9374376039933447
81,natalizumab,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,kappa,ZU,IgG4,Approved,251.745704994274,79.5,900.0,9.7,8.843,0.01877,0.0,0.8228838815638237,8.763999999999998,-0.01,1.0639936735398734,1.5247920133111483
82,necitumumab,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,kappa,HU,IgG1,Approved,198.599891054805,76.5,600.0,10.807,9.9,0.0204,0.0,1.3005776956421913,8.770999999999999,-0.02,1.045455831771032,1.3104825291181363
83,nimotuzumab,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,kappa,ZU,IgG1,Approved,15.1316498281991,65.5,900.0,25.0,8.884,0.04357,0.0,-0.5855046313570632,8.464,-0.02,1.3186788480077605,3.424292845257904
84,nivolumab,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,kappa,HU,IgG4-CPPC,Approved,178.809228510513,66.0,900.0,9.023,8.655,0.02743,0.13517545913870355,2.4180401288815534,8.853,-0.01,1.153877024631619,1.3244592346089852
85,obinutuzumab,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,kappa,ZU,IgG1-glyco,Approved,176.441448316105,73.0,600.0,10.641,8.964,0.0128,0.11278530198519128,1.83157297498583,8.799999999999999,-0.01,0.9505575375720098,1.6295880149812734
86,ocrelizumab,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,137.774414120228,70.5,300.0,9.911,8.83,0.0237,0.0,17.8819936959764,9.531999999999998,0.01,1.1284919906404223,1.6726591760299625
87,ofatumumab,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,kappa,HU,IgG1,Approved,249.752167259925,68.0,800.0,9.729,9.524,0.02874,0.0,1.2096991584336332,9.248,-0.02,1.1221425835603067,1.1767054908485857
88,olaratumab,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,kappa,HU,IgG1,Phase 2,141.936047698606,62.5,700.0,10.609,8.957,0.2885,0.48314257453880055,0.3103945521038816,9.417,-0.02,1.3160671759946407,2.584359400998336
89,olokizumab,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,kappa,ZU,IgG4-CPPC,Phase 2,115.258271448835,69.0,700.0,9.908,8.973,0.04469,0.0,-0.5026150619501847,8.749,-0.03,1.10536901058665,1.2292845257903493
90,omalizumab,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,kappa,ZU,IgG1,Approved,150.447109488797,77.5,800.0,9.519,8.744,0.04511,0.0,-0.4382784241093604,8.537999999999998,-0.02,1.116104955964963,1.1660565723793677
91,onartuzumab,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,kappa,ZU,IgG1-One-armed,Phase 3,147.933138230081,80.0,800.0,9.919,8.869,0.04311,0.0,-0.04666204256485199,8.911,-0.02,1.1192805146585436,1.1866888519134775
92,otelixizumab,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,lambda,XIZUb,IgG1-no-glyco,Phase 3,152.082452769047,75.5,1000.0,9.082,8.72,0.08814,0.0,4.438287496308697,8.719,-0.02,1.1278218851815427,1.3976705490848589
93,otlertuzumab,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,kappa,ZU,scFv-Fc,Phase 2,149.600653819379,68.5,600.0,10.959,10.267,0.07229,0.0,2.2609834310984502,9.516,-0.03,1.171753052308772,1.7816971713810317
94,ozanezumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,kappa,ZU,IgG1,Phase 2,97.0746878906631,67.0,0.0,10.034,8.632,0.05569,0.7713140231818809,27.692332066403335,9.045999999999998,0.45,2.0293580052025075,4.452579034941763
95,palivizumab,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,kappa,ZU,IgG1,Approved,243.119697931277,79.5,900.0,9.332,8.705,0.03666,0.0,-0.852684669073482,8.490999999999998,-0.03,1.1188467277896599,2.876539101497504
96,panitumumab,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,kappa,HU,IgG2,Approved,179.58785735722,78.5,900.0,9.479,8.799,0.03631,0.0,-1.0846051804108647,8.42,-0.03,1.0620884253110507,1.1826955074875207
97,panobacumab,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,kappa,HU,IgM,Phase 2,107.597685805881,69.0,900.0,9.827,8.85,0.02071,0.0,-0.41557666008956523,8.992000000000003,-0.01,1.212666778322873,1.896838602329451
98,parsatuzumab,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,40.0193274662591,64.5,900.0,9.109,8.781,0.08654,0.13444361072719918,7.400358629404036,8.650999999999998,0.12,10.046526919824307,17.395673876871882
99,patritumab,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,kappa,HU,IgG1,Phase 3,68.7744200744969,71.5,600.0,10.15,9.321,0.05371,0.520072725150479,13.086408099747162,9.444999999999999,0.04,2.346216519385749,4.346089850249584
100,pembrolizumab,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,kappa,ZU,IgG4-CPPC,Approved,64.9089832561903,66.0,500.0,11.073,13.477,0.0334,0.3004254416492691,5.622346926584057,10.918,0.01,1.2770624602017013,2.2342762063227957
101,pertuzumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,kappa,ZU,IgG1,Approved,31.426915083696,78.5,700.0,10.112,8.913,0.03917,0.0,-0.2038247903172226,8.597,-0.04,1.2135825800677662,1.691846921797005
102,pinatuzumab,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,kappa,ZU,IgG1-ADC,Phase 2,130.580856755494,79.0,800.0,9.224,8.827,0.06846,0.011366283122060918,0.5895214803654546,8.774000000000001,-0.02,1.2721713049670622,2.4851913477537435
103,polatuzumab,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,225.055164066148,74.0,1000.0,8.763,8.67,0.05931,0.0,-1.0031675074379403,8.263999999999998,-0.05,1.3625371953152638,3.622628951747088
104,ponezumab,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,kappa,ZU,IgG2,Phase 2,16.9578603061903,61.0,800.0,10.499,9.004,0.1568,0.07435934054232925,-0.2399076202624778,8.678999999999997,-0.03,3.130063194362313,6.623627287853577
105,radretumab,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,kappa,HU,scFv-CH,Phase 2,151.171797090559,77.0,900.0,9.514,8.69,0.001743,0.1336773168637967,3.38469852929544,8.858000000000002,0.0,1.259503881510183,3.286522462562396
106,ramucirumab,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,kappa,HU,IgG1,Approved,90.6680959632434,66.0,900.0,9.43,8.705,0.02434,0.0,0.01584428161675064,8.581999999999999,-0.02,1.0548930060222366,1.2499168053244594
107,ranibizumab,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,kappa,ZU,Fab,Approved,41.4478661761276,65.0,300.0,12.142,18.059,0.0942,0.0,7.925273438937659,10.057999999999998,0.02,1.6071237071180915,3.1381031613976704
108,reslizumab,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,kappa,ZU,IgG4,Approved,191.56852636743,75.5,700.0,9.824,8.9,0.06217,0.2302901027079426,1.7393013527342458,8.863999999999999,0.0,1.2514632393209744,2.0232945091514143
109,rilotumumab,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,kappa,HU,IgG2,Phase 3,173.0777953220001,79.0,500.0,12.633,17.684,1.2728,0.16002193426347533,2.1265795851744866,10.393,0.0,1.130870798292275,2.3730337078651687
110,rituximab,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,kappa,XI,IgG1,Approved,164.141012459454,69.0,700.0,10.797,9.109,0.025,0.38386574676405544,2.1331376064924,10.146999999999998,-0.01,1.1902969075892453,2.929118136439268
111,robatumumab,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,kappa,HU,IgG1,Phase 2,117.115691209503,80.0,0.0,9.507,8.969,0.04534,0.2666565076523404,29.64509490013043,9.752,0.14,5.219351315649218,8.246256239600665
112,romosozumab,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,kappa,ZU,IgG2,Phase 3,227.687243355563,76.0,1000.0,9.18,8.648,0.02831,0.0,-1.019466113704991,8.426999999999998,-0.03,1.0073451432896823,1.4682196339434277
113,sarilumab,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,kappa,HU,IgG1,Phase 3,181.786077494252,64.0,900.0,8.989,8.687,0.04986,0.0,1.1138239186948327,8.71,-0.01,1.1869120226240375,2.16838602329451
114,secukinumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,kappa,HU,IgG1,Approved,148.958795741179,72.0,800.0,11.389,8.906,0.0492,0.0,-0.5847129696615325,8.360999999999999,-0.04,1.0888623977969765,1.694756554307116
115,seribantumab,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,lambda,HU,IgG2,Phase 2,189.983139937075,77.5,300.0,10.418,8.998,0.1544,0.0,21.20826376243033,9.787,0.01,1.2374308746890108,2.9737104825291185
116,sifalimumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,kappa,HU,IgG1,Phase 2,158.632741637798,67.0,800.0,9.651,8.773,0.01314,0.060620218678356444,2.1004838375769133,9.019999999999998,-0.02,2.5954190810692452,2.497171381031614
117,siltuximab,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,kappa,XI,IgG1,Approved,95.66717325032879,64.5,600.0,10.999,12.076,0.0133,0.0,2.63765782682196,9.419999999999998,-0.01,1.1753257510105992,1.5498127340823968
118,simtuzumab,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,kappa,ZU,IgG4-CPPC,Phase 2,191.43536575903,66.5,800.0,10.407,9.571,0.1421,0.33687521946111343,0.8806858247165398,9.098,0.0,6.008055924888647,10.411314475873544
119,sirukumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,kappa,HU,IgG1,Phase 3,109.80671187862,68.0,0.0,11.26,10.756,0.03969,0.3598739363069841,29.64509490013043,10.790000000000001,0.08,2.1745394240741476,9.657903494176374
120,tabalumab,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,kappa,HU,IgG4-CPPC,Phase 3,121.595499055525,64.0,700.0,10.847,9.87,0.0618,0.0,1.9553606921790134,9.126999999999997,-0.01,1.2603857827328724,3.6818635607321126
121,tanezumab,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,kappa,ZU,IgG2,Phase 3,48.8637659879149,75.5,700.0,12.386,10.689,0.0166,0.22961169870509723,2.171174192066317,9.247999999999996,-0.01,1.3963581317475169,4.827715355805243
122,teplizumab,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,kappa,ZU,IgG1AA-mut,Phase 3,150.875164847252,64.5,1000.0,8.786,8.647,0.06126,0.3112823502113737,11.16712056040071,9.364999999999997,0.02,1.6739762600577706,3.8449251247920126
123,tigatuzumab,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,kappa,ZU,IgG1,Phase 2,178.9678004885262,64.5,700.0,10.02,8.732,0.0029,0.1287699032014038,5.48928624336508,8.7,-0.01,1.1729393976465865,1.702621722846442
124,tildrakizumab,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,kappa,ZU,IgG1,Phase 3,181.888072908582,77.5,600.0,11.079,9.868,-0.005,0.0,0.8149033177938515,8.727999999999996,-0.01,1.1862533869555876,1.7690515806988354
125,tocilizumab,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,kappa,ZU,IgG1,Approved,139.649467055541,91.5,900.0,9.088,8.777,0.04516,0.0,1.3182827059504583,8.902,0.0,1.135550122276806,2.8079866888519134
126,tovetumab,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,kappa,HU,IgG2,Phase 2,277.1807519763495,63.5,900.0,8.673,8.634,0.0131,0.0,2.24515352101381,8.808,-0.01,1.3521453590768024,2.951685393258427
127,tralokinumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,lambda,HU,IgG4,Phase 3,121.427053055544,63.0,800.0,10.262,8.987,0.007743,0.1573940014543203,4.813687111140356,8.799999999999999,0.09,1.2862877834978765,2.3154742096505823
128,trastuzumab,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,kappa,ZU,IgG1,Approved,159.477626783881,78.5,800.0,9.657,8.752,0.04383,0.0,2.0381268958261267,8.843000000000002,-0.02,1.0634546075337579,1.3364392678868553
129,tremelimumab,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,kappa,HU,IgG2,Phase 3,229.592510711403,75.0,0.0,11.557,19.316,0.01757,0.14549710334871435,29.64509490013043,11.241999999999999,0.0,1.2112385448287972,1.9653910149750415
130,urelumab,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,kappa,HU,IgG4,Phase 2,143.923958410927,66.0,0.0,11.161,12.985,0.01389,0.0,29.64509490013043,9.368999999999998,0.07,1.1463753799390732,1.5314475873544091
131,ustekinumab,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,kappa,HU,IgG1,Approved,152.722928253076,69.5,1000.0,8.783,8.64,0.02254,0.15365337079491923,0.4242355921805543,8.632999999999997,-0.01,2.184532464212374,5.074209650582363
132,vedolizumab,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,kappa,ZU,IgG1AA-mut,Approved,221.762037454388,80.5,600.0,10.942,12.307,0.06906,0.0,0.3881784429681827,8.986,-0.02,1.1526713187714972,1.584026622296173
133,veltuzumab,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,kappa,ZU,IgG1,Phase 2,224.9535174226083,70.0,700.0,11.092,9.725,0.0399,0.0,4.831871310872237,8.791999999999998,-0.02,0.8888091523389052,1.2112359550561798
134,visilizumab,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,kappa,ZU,IgG2,Phase 3,242.006376767476,71.0,0.0,9.007,8.695,0.0576,0.4180705492837355,21.988193058351637,9.145999999999999,0.01,1.8807718205977446,4.799334442595674
135,zalutumumab,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,kappa,HU,IgG1,Phase 3,200.506689606493,72.5,900.0,9.335,8.738,0.04983,0.0,-0.796790150018558,8.414999999999997,-0.03,1.2843634959160908,2.896505823627288
136,zanolimumab,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,kappa,HU,IgG1,Phase 3,116.367687863994,80.5,700.0,9.586,8.768,0.02569,0.12712772521052765,1.4579366607851665,8.609999999999998,-0.01,1.1022619931841995,1.4555740432612314

